In Reply We are thankful for the interest shown by Spencer-Segal in our meta-analysis of corticosteroid use for treatment of sepsis.1 We welcome her thoughtful comments regarding additional directions for future trials.
First, Spencer-Segal pointed out the differences between the drugs regarding outcomes for corticosteroid use in patients with sepsis. We agree that not all corticosteroids are the same. A network meta-analysis2 concluded that methylprednisolone is less likely to result in shock reversal than hydrocortisone, though there is no clear evidence that any corticosteroid is better than another in reducing mortality.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Zhang Y, Xu J, Fang F. Future Directions for Corticosteroids in Treatment of Sepsis—Reply. JAMA Intern Med. 2019;179(6):845. doi:10.1001/jamainternmed.2019.0856
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: